Short answer: Generally, someone who took a GLP-1 drug such as Ozempic, Wegovy or Mounjaro and was then diagnosed with a serious stomach or bowel injury. For gastroparesis specifically, the MDL court ruled on August 15, 2025 that the diagnosis must be supported by a gastric emptying study, an objective test, not symptoms alone.
Plaintiffs’ leadership told the court that most cases in MDL 3094 allege gastroparesis, so this ruling decides which of them can go forward. Other injuries pleaded in the MDL include ileus and intestinal obstruction, gallbladder injury and severe, repeated vomiting.
- Helps a claim: a prescription record, a diagnosis after starting the drug, a gastric emptying study (for gastroparesis), and hospital or ER records.
- Weakens a claim: no objective test, or stomach problems documented before the drug was started.
- Deadlines: each state sets its own filing deadline, often starting when you learned of the injury.
A free, confidential case review can look at your records and the timeline. See the Ozempic lawsuit guide for more.
Full guide: Ozempic gastroparesis lawsuit: what to know in 2026
SourcesRule 702 opinionE.D. Pa., 15 Aug 2025CMO No. 18E.D. Pa., MDL 3094MDL 3094 court pageE.D. Pa.



